| Applied Genetic Technologies is a clinical-stage biotechnology company that uses a proprietary gene therapy platform to develop transformational genetic therapies for patients suffering from rare and debilitating diseases. Co. focuses on the field of ophthalmology, where it has clinical programs in X-linked retinitis pigmentosa and achromatopsia. Co. also has clinical-stage program in optogenetics, and pre-clinical programs in central nervous system, and several other ophthalmology, and otology indications. Co. has developed technological capabilities in the design, construction and manufacture of viral vectors using adeno-associated virus technology. We show 32 historical shares outstanding datapoints in our coverage of AGTC's shares outstanding history.|
Understanding the changing numbers of AGTC shares outstanding — and
comprehending the concept of differing number of shares outstanding in general comparing companies like AGTC versus peers —
is critical for investors. Many "beginner" or "novice" investors will look at one stock trading at a price of $10 per share and another trading at
a price of $20 per share and think the latter company is worth twice as much. Of course, that is a completely meaningless comparison without also knowing how many shares outstanding there are for each of the two companies.
Furthermore, via issuance of new shares over time, or the repurchase of existing shares, the number of shares outstanding can fluctuate over the course of history.
With this page we aim to empower investors researching AGTC by allowing them to research AGTC shares outstanding history
as well as any other stock in our coverage universe.